2026 Q1 -tulosraportti
88 päivää sitten
‧1 t 11 min
0,41 DKK/osake
Viimeisin osinko
0,63%Tuotto/v
Tarjoustasot
Nasdaq Copenhagen
Määrä
Osto
-
Myynti
Määrä
-
Viimeisimmät kaupat
| Aika | Hinta | Määrä | Ostaja | Myyjä |
|---|---|---|---|---|
| 176 | - | - | ||
| 215 | - | - | ||
| 38 | - | - | ||
| 177 | - | - | ||
| 214 | - | - |
Välittäjätilasto
Dataa ei löytynyt
Yhtiötapahtumat
Datan lähde: FactSet, Quartr| Seuraava tapahtuma | |
|---|---|
2026 Q2 -tulosraportti 6.5. | 3 päivää |
| Menneet tapahtumat | ||
|---|---|---|
2026 Q1 -tulosraportti 4.2. | ||
2025 Q4 -tulosraportti 5.11.2025 | ||
2025 Q3 -tulosraportti 22.8.2025 | ||
2025 Q2 -tulosraportti 7.5.2025 | ||
2025 Q1 -tulosraportti 30.1.2025 |
Asiakkaat katsoivat myös
Foorumi
Liity keskusteluun Nordnet Socialissa
Kirjaudu
·2 päivää sitten · MuokattuSo I have bought more shares before the earnings report and I have done that because, among other things, Ambu has taken a beating on the share price due to the tariff, but there is, for example, no tariff from their production in Mexico. Britt and the CFO have bought shares and then they have paid dividends and made share buybacks and one only does that if things are going well. They have gotten their endoscope portfolio EU marked in Europe. There are probably also some less good things, but I believe that the positive things are greater and then there is also just 6,31% short, which must be covered if I am right. Good luck with the earnings report.·6 t sittenBritt bought 20,000 shares for 1,632,000 kr at a price of 81.60. The CFO 10,500 shares for 870,450 kr at a price of 82.90. The latest price targets. DNB Carneige 125 ➡️ 105 "buy" Danske Bank 100 ➡️ 90 "buy" ABG Sunbdal 120 ➡️ 100 "buy" JP Morgan 90 ➡️ 78 "Neutral" 7 "buy" recommendations, 3 "hold" and no "sell" Ambu's Japanese competitor cut 2,000 positions due to a 31% drop in operating profit, as well as FDA concerns regarding the company's medical equipment. So less competition from that side.
·2 päivää sittenI have invested in AMBU today, both in free funds and pension depot, I think it has fallen a lot recently, I bought at price 64.50, I don't think it will go completely wrong. Good weekend.
3 päivää sitten3 päivää sitten
·2 päivää sittenI wonder, Ambu is the global market leader in the field, but the business is not doing so well, is it because there are few countries that use single-use endoscopy?
·2 päivää sittenOf course, it can always get better. But why do you think it's not performing so well? I am quite impressed with the progress. Sold in 2023 as I didn't think they could live up to the high market value. They probably still can't, but they have come a long way and the share price is the same.
·3 päivää sitten · MuokattuSo more have been bought at price 61.50 - Reason: Ambu is trading below both SMA50 and SMA200, which is a classic Death Cross-formation that typically signals increasing pessimism. But unfortunately there is no technical support in the price chart. When both technical investors and algorithms see this pattern, they sell automatically. So I have bought more, as I believe more in the company and look forward to 06. May.
·3 päivää sittenStrange that only AMBU is falling when everything else is rising….
Yllä olevat kommentit ovat peräisin Nordnetin sosiaalisen verkoston Nordnet Socialin käyttäjiltä, eikä niitä ole muokattu eikä Nordnet ole tarkastanut niitä etukäteen. Ne eivät tarkoita, että Nordnet tarjoaisi sijoitusneuvoja tai sijoitussuosituksia. Nordnet ei ota vastuuta kommenteista.
Uutiset
Tämän sivun uutiset ja/tai sijoitussuositukset tai otteet niistä sekä niihin liittyvät linkit ovat mainitun tahon tuottamia ja toimittamia. Nordnet ei ole osallistunut materiaalin laatimiseen, eikä ole tarkistanut sen sisältöä tai tehnyt sisältöön muutoksia. Lue lisää sijoitussuosituksista.
2026 Q1 -tulosraportti
88 päivää sitten
‧1 t 11 min
0,41 DKK/osake
Viimeisin osinko
0,63%Tuotto/v
Uutiset
Tämän sivun uutiset ja/tai sijoitussuositukset tai otteet niistä sekä niihin liittyvät linkit ovat mainitun tahon tuottamia ja toimittamia. Nordnet ei ole osallistunut materiaalin laatimiseen, eikä ole tarkistanut sen sisältöä tai tehnyt sisältöön muutoksia. Lue lisää sijoitussuosituksista.
Foorumi
Liity keskusteluun Nordnet Socialissa
Kirjaudu
- ·2 päivää sitten · MuokattuSo I have bought more shares before the earnings report and I have done that because, among other things, Ambu has taken a beating on the share price due to the tariff, but there is, for example, no tariff from their production in Mexico. Britt and the CFO have bought shares and then they have paid dividends and made share buybacks and one only does that if things are going well. They have gotten their endoscope portfolio EU marked in Europe. There are probably also some less good things, but I believe that the positive things are greater and then there is also just 6,31% short, which must be covered if I am right. Good luck with the earnings report.·6 t sittenBritt bought 20,000 shares for 1,632,000 kr at a price of 81.60. The CFO 10,500 shares for 870,450 kr at a price of 82.90. The latest price targets. DNB Carneige 125 ➡️ 105 "buy" Danske Bank 100 ➡️ 90 "buy" ABG Sunbdal 120 ➡️ 100 "buy" JP Morgan 90 ➡️ 78 "Neutral" 7 "buy" recommendations, 3 "hold" and no "sell" Ambu's Japanese competitor cut 2,000 positions due to a 31% drop in operating profit, as well as FDA concerns regarding the company's medical equipment. So less competition from that side.
- ·2 päivää sittenI have invested in AMBU today, both in free funds and pension depot, I think it has fallen a lot recently, I bought at price 64.50, I don't think it will go completely wrong. Good weekend.
- 3 päivää sitten3 päivää sitten·2 päivää sittenI wonder, Ambu is the global market leader in the field, but the business is not doing so well, is it because there are few countries that use single-use endoscopy?·2 päivää sittenOf course, it can always get better. But why do you think it's not performing so well? I am quite impressed with the progress. Sold in 2023 as I didn't think they could live up to the high market value. They probably still can't, but they have come a long way and the share price is the same.
- ·3 päivää sitten · MuokattuSo more have been bought at price 61.50 - Reason: Ambu is trading below both SMA50 and SMA200, which is a classic Death Cross-formation that typically signals increasing pessimism. But unfortunately there is no technical support in the price chart. When both technical investors and algorithms see this pattern, they sell automatically. So I have bought more, as I believe more in the company and look forward to 06. May.
- ·3 päivää sittenStrange that only AMBU is falling when everything else is rising….
Yllä olevat kommentit ovat peräisin Nordnetin sosiaalisen verkoston Nordnet Socialin käyttäjiltä, eikä niitä ole muokattu eikä Nordnet ole tarkastanut niitä etukäteen. Ne eivät tarkoita, että Nordnet tarjoaisi sijoitusneuvoja tai sijoitussuosituksia. Nordnet ei ota vastuuta kommenteista.
Tarjoustasot
Nasdaq Copenhagen
Määrä
Osto
-
Myynti
Määrä
-
Viimeisimmät kaupat
| Aika | Hinta | Määrä | Ostaja | Myyjä |
|---|---|---|---|---|
| 176 | - | - | ||
| 215 | - | - | ||
| 38 | - | - | ||
| 177 | - | - | ||
| 214 | - | - |
Välittäjätilasto
Dataa ei löytynyt
Asiakkaat katsoivat myös
Yhtiötapahtumat
Datan lähde: FactSet, Quartr| Seuraava tapahtuma | |
|---|---|
2026 Q2 -tulosraportti 6.5. | 3 päivää |
| Menneet tapahtumat | ||
|---|---|---|
2026 Q1 -tulosraportti 4.2. | ||
2025 Q4 -tulosraportti 5.11.2025 | ||
2025 Q3 -tulosraportti 22.8.2025 | ||
2025 Q2 -tulosraportti 7.5.2025 | ||
2025 Q1 -tulosraportti 30.1.2025 |
2026 Q1 -tulosraportti
88 päivää sitten
‧1 t 11 min
Uutiset
Tämän sivun uutiset ja/tai sijoitussuositukset tai otteet niistä sekä niihin liittyvät linkit ovat mainitun tahon tuottamia ja toimittamia. Nordnet ei ole osallistunut materiaalin laatimiseen, eikä ole tarkistanut sen sisältöä tai tehnyt sisältöön muutoksia. Lue lisää sijoitussuosituksista.
Yhtiötapahtumat
Datan lähde: FactSet, Quartr| Seuraava tapahtuma | |
|---|---|
2026 Q2 -tulosraportti 6.5. | 3 päivää |
| Menneet tapahtumat | ||
|---|---|---|
2026 Q1 -tulosraportti 4.2. | ||
2025 Q4 -tulosraportti 5.11.2025 | ||
2025 Q3 -tulosraportti 22.8.2025 | ||
2025 Q2 -tulosraportti 7.5.2025 | ||
2025 Q1 -tulosraportti 30.1.2025 |
0,41 DKK/osake
Viimeisin osinko
0,63%Tuotto/v
Foorumi
Liity keskusteluun Nordnet Socialissa
Kirjaudu
- ·2 päivää sitten · MuokattuSo I have bought more shares before the earnings report and I have done that because, among other things, Ambu has taken a beating on the share price due to the tariff, but there is, for example, no tariff from their production in Mexico. Britt and the CFO have bought shares and then they have paid dividends and made share buybacks and one only does that if things are going well. They have gotten their endoscope portfolio EU marked in Europe. There are probably also some less good things, but I believe that the positive things are greater and then there is also just 6,31% short, which must be covered if I am right. Good luck with the earnings report.·6 t sittenBritt bought 20,000 shares for 1,632,000 kr at a price of 81.60. The CFO 10,500 shares for 870,450 kr at a price of 82.90. The latest price targets. DNB Carneige 125 ➡️ 105 "buy" Danske Bank 100 ➡️ 90 "buy" ABG Sunbdal 120 ➡️ 100 "buy" JP Morgan 90 ➡️ 78 "Neutral" 7 "buy" recommendations, 3 "hold" and no "sell" Ambu's Japanese competitor cut 2,000 positions due to a 31% drop in operating profit, as well as FDA concerns regarding the company's medical equipment. So less competition from that side.
- ·2 päivää sittenI have invested in AMBU today, both in free funds and pension depot, I think it has fallen a lot recently, I bought at price 64.50, I don't think it will go completely wrong. Good weekend.
- 3 päivää sitten3 päivää sitten·2 päivää sittenI wonder, Ambu is the global market leader in the field, but the business is not doing so well, is it because there are few countries that use single-use endoscopy?·2 päivää sittenOf course, it can always get better. But why do you think it's not performing so well? I am quite impressed with the progress. Sold in 2023 as I didn't think they could live up to the high market value. They probably still can't, but they have come a long way and the share price is the same.
- ·3 päivää sitten · MuokattuSo more have been bought at price 61.50 - Reason: Ambu is trading below both SMA50 and SMA200, which is a classic Death Cross-formation that typically signals increasing pessimism. But unfortunately there is no technical support in the price chart. When both technical investors and algorithms see this pattern, they sell automatically. So I have bought more, as I believe more in the company and look forward to 06. May.
- ·3 päivää sittenStrange that only AMBU is falling when everything else is rising….
Yllä olevat kommentit ovat peräisin Nordnetin sosiaalisen verkoston Nordnet Socialin käyttäjiltä, eikä niitä ole muokattu eikä Nordnet ole tarkastanut niitä etukäteen. Ne eivät tarkoita, että Nordnet tarjoaisi sijoitusneuvoja tai sijoitussuosituksia. Nordnet ei ota vastuuta kommenteista.
Tarjoustasot
Nasdaq Copenhagen
Määrä
Osto
-
Myynti
Määrä
-
Viimeisimmät kaupat
| Aika | Hinta | Määrä | Ostaja | Myyjä |
|---|---|---|---|---|
| 176 | - | - | ||
| 215 | - | - | ||
| 38 | - | - | ||
| 177 | - | - | ||
| 214 | - | - |
Välittäjätilasto
Dataa ei löytynyt